NASDAQ GM
DRTX

Durata Therapeutics, Inc.

Shareholder Corporation Litigation

Rigrodsky & Long, P.A. Announces Investigation Of Durata Therapeutics, Inc. (NASDAQ GM: DRTX) Buyout

Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Durata Therapeutics, Inc. (“Durata” or the “Company”) (NASDAQ GM: DRTX) regarding possible breaches of fiduciary duties and other violations of law related to the Company’s entry into an agreement to be acquired by Actavis plc (“Actavis”) (NYSE: ACT), in a transaction valued at approximately $675 million.

Under the terms of the agreement, public shareholders of Durata would receive $23.00 in cash, and up to $5.00 per share in a Contingent Value Right, for each share of Durata they own.

The investigation concerns whether Durata’s board of directors failed to adequately shop the Company and obtain the best possible value for Durata’s shareholders before entering into an agreement with Actavis.  According to Yahoo! Finance, at least one analyst has issued a price target for Durata stock at $26.00 per share.

If you own the common stock of Durata and purchased your shares before October 6, 2014, if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Seth D. Rigrodsky or Gina M. Serra at Rigrodsky & Long, P.A., 2 Righter Parkway, Suite 120, Wilmington, DE 19803, by telephone at (888) 969-4242; by e-mail to info@rl-legal.com.  

Rigrodsky & Long, P.A., with offices in Wilmington, Delaware and Garden City, New York, regularly prosecutes securities class, derivative and direct actions, shareholder rights litigation and corporate governance litigation, on behalf of shareholders in states and federal courts throughout the United States.

Attorney advertising.  Prior results do not guarantee a similar outcome.